Copyright
©The Author(s) 2022.
World J Transplant. Jul 18, 2022; 12(7): 195-203
Published online Jul 18, 2022. doi: 10.5500/wjt.v12.i7.195
Published online Jul 18, 2022. doi: 10.5500/wjt.v12.i7.195
Preoperative | Brustia et al[8] | Xu et al[9] | Rao et al[7] | |||
ERAS group, n = 10 | CONTROL group, n = 20 | ERAS group, n = 40 | CONTROL group, n = 53 | ERAS group, n = 54 | CONTROL group, n = 74 | |
Gender | ||||||
Male | 8 | 17 | 35 | 46 | 40 | 58 |
Female | 2 | 3 | 5 | 7 | 1 | 16 |
Age, yr | 60.1 (52.5-66.1) | 58.2 (52.6-65.3) | 49.5 (40-56.8) | 53 (47-59) | 52.4 + 15.2 | 55.8 + 14.3 |
Primary cause | ||||||
Alcohol | 7 (70%) | 9 (45%) | 7 | 3 | 6 (11.1) | 10 (13.5) |
Viral cirrhosis | 7 (70%) | 10 (50%) | 11 | 16 | 30 (55.6) | 40 (54.1) |
HBV | 2 (20%) | 4 (20%) | NA | NA | NA | NA |
HCV | 6 (60%) | 8 (40%) | NA | NA | NA | NA |
Metabolic syndrome | 2 (20%) | 4 (20%) | NA | NA | NA | NA |
Biliary disease | 0 | 3 (15%) | NA | NA | NA | NA |
HCC | 9 (90%) | 9 (45%) | 17 | 24 | 18 (33.3) | 24 (32.4) |
MELD score | 7 (6-10) | 7 (6-9) | 14 (9-22) | 17 (14-19) | 7.7 + 3.2 | 7.9 + 4.6 |
Intraoperative | ||||||
Operative time | 6.0 (5.9-8.4) h | 6.7 (5.7-8.2) h | 443.7 + 85.3min | 453.5 + 62.3min | 265 (215-360) min | 325 (275-455) min |
Anhepatic period | NA | NA | 44.3 + 5.2 min | 42.7 + 4.2 min | 45 (35-70) min | 60 (50-75) min |
Blood loss | NA | NA | 775 (525-1000) mL | 800 (600-1000) mL | 1100 (300-4200) mL | 2900 (1600-7000) mL |
Hypothermia during the operation (n, %) | NA | NA | 0 | 12% | 0 | 0 |
Postoperative | ||||||
Early extubation (h) | 2 (0-2) | 7.5 (4.5-13.0) | 0 | 6 (5.5-8) | NA | NA |
ICU stay (d) | 3 (2-4) | 4.5 (3.0-8.3) | 2 (2-3) | 4 (4-5) | 2 (1-7) | 5 (3-15) |
Complications (n, %) | 5 (50%) | 16 (80%) | 9 (22.5%) | 26 (49.1%) | 10 (18.5%) | 20 (27%) |
Pain score after operation | 3 (1.0-4.0) POD | 4.5 (2.7-6.) POD | 2.45+ 0.54 | 3.02+0.44 | NA | NA |
Postoperative hospital stay (d) | 9.5 (9.0-10.5) | 18 (14.3-24.3) | 14.5 (12-17) | 16 (15-18) | 18 (15-32) | 28 (23-35) |
Readmission within 30 d after discharge | NA | NA | 0 | 0 | 0 | 0 |
Preoperative | Brustia et al[8] | Xu et al[9] | Rao et al[7] |
1 Outpatient counseling and information | √ | √ | √ |
2 Preoperative carbohydrate loading | √ | √ | √ |
3 Absence of preanesthetic medication (anxiolytic) | √ | ||
Intraoperative | |||
4 Antimicrobial prophylaxis and skin preparation | √ | ||
5 Prevention of intraoperative hypothermia | √ | √ | |
6 Incision | √ | ||
7 Adapted IV filling | √ | √ | √ |
8 Temporary portocaval anastomosis | √ | ||
9 No prophylactic nasogastric intubation | √ | √ | |
10 No prophylactic abdominal drainage | √ | √ | |
11 Prevention of postoperative nausea and vomiting | √ | ||
12 Antithrombotic prophylaxis and/oranti-aggregation | √ | √ | |
13 Early extubation (< 6 h after the endof lt) | √ | √ | √ |
Postoperative | |||
14 Early mobilization (POD1) | √ | √ | √ |
15 Patient-controlled analgesia | √ | √ | |
16 Gastric probe removal POD1 | √ | √ | |
17 Clear liquid per OS POD1 | √ | √ | √ |
18 Enteral feeding per OS POD1 | √ | √ | √ |
19 Stop IV fluids POD1 | √ | √ | |
20 Per OS analgesia (POD2) | √ | √ | |
21 Abdominal drain removal POD2 | √ | ||
22 Urinary probe removal POD2 | √ | √ | √ |
23 Stop IV analgesia POD3 | √ | √ | |
24 Independent mobilization POD3 | √ | √ | √ |
25 Daily revision of discharge criteria | √ | √ | √ |
26 Audit | √ | √ | √ |
- Citation: Katsanos G, Karakasi KE, Antoniadis N, Vasileiadou S, Kofinas A, Morsi-Yeroyannis A, Michailidou E, Goulis I, Sinakos E, Giouleme O, Oikonomou IM, Evlavis G, Tsakiris G, Massa E, Mouloudi E, Tsoulfas G. Enhanced recovery after surgery in liver transplantation: Challenges and feasibility. World J Transplant 2022; 12(7): 195-203
- URL: https://www.wjgnet.com/2220-3230/full/v12/i7/195.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i7.195